Paper · 19821490
Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma.
Nord H and 9 others. Int J Cancer, 2010. Cited by 51 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. Papers, record 19821490. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19821490
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gene Amplification | Major topic |
| Genetic Predisposition to Disease | Major topic |
| Urinary Bladder | Major topic |
| Urinary Bladder Neoplasms | Major topic |
| 14-3-3 Proteins | |
| Cell Cycle Proteins | |
| Chromosome Aberrations | |
| Comparative Genomic Hybridization | |
| Cyclin D1 | |
| Female | |
| Gene Dosage | |
| Gene Expression Profiling | |
| Gene Expression Regulation, Neoplastic | |
| Humans | |
| Male | |
| Neoplasm Recurrence, Local | |
| Neoplasm Staging | |
| Proto-Oncogene Proteins c-mdm2 | |
| Proto-Oncogene Proteins c-myc | |
| Receptor, Fibroblast Growth Factor, Type 3 | |
| Syndecan-4 | |
| Trans-Activators |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 51 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,633,326 | Advances in FGF/FGFR Signaling: Implications for Disease and Therapy. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42633326 | PubMed |
| 40,883,021 | Bladder Cancer: Role of Circular RNAs in Oncogenesis, Tumor Suppression, and Therapeutic Target Identification. | Cancer Genomics Proteomics | 2025 | https://conductscience.org/library/papers/40883021 | PubMed |
| 40,316,856 | Integrating analysis of multi-omics summary data identifies novel plasma protein biomarkers and drug targets for bladder cancer. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40316856 | PubMed |
| 38,292,182 | Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration. | Genes Dis | 2024 | https://conductscience.org/library/papers/38292182 | PubMed |
| 36,087,093 | Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer. | Mol Oncol | 2022 | https://conductscience.org/library/papers/36087093 | PubMed |
| 35,838,190 | Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors. | Cancer Sci | 2023 | https://conductscience.org/library/papers/35838190 | PubMed |
| 34,876,130 | Intricate crosstalk between MYB and noncoding RNAs in cancer. | Cancer Cell Int | 2021 | https://conductscience.org/library/papers/34876130 | PubMed |
| 34,849,009 | Novel Ferroptosis-Related Multigene Prognostic Models for Patients with Bladder Cancer. | Int J Gen Med | 2021 | https://conductscience.org/library/papers/34849009 | PubMed |
| 33,810,567 | Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer. | Biomolecules | 2021 | https://conductscience.org/library/papers/33810567 | PubMed |
| 33,672,869 | Urinary Cell-Free DNA in Bladder Cancer Detection. | Diagnostics (Basel) | 2021 | https://conductscience.org/library/papers/33672869 | PubMed |
1 to 10 of 32
See all 32 cited byGenes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CCND1 | 595 | PubTator's text mining | https://conductscience.org/library/genes/595 | NCBI Gene |
| FGFR3 | 2,261 | PubTator's text mining | https://conductscience.org/library/genes/2261 | NCBI Gene |
| MDM2 | 4,193 | PubTator's text mining | https://conductscience.org/library/genes/4193 | NCBI Gene |
| MYBL2 | 4,605 | PubTator's text mining | https://conductscience.org/library/genes/4605 | NCBI Gene |
| MYC | 4,609 | PubTator's text mining | https://conductscience.org/library/genes/4609 | NCBI Gene |
| SDC4 | 6,385 | PubTator's text mining | https://conductscience.org/library/genes/6385 | NCBI Gene |
| YWHAB | 7,529 | PubTator's text mining | https://conductscience.org/library/genes/7529 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19821490
GET https://conductscience.org/api/papers/v1/19821490/cited_by?page=2